Drug Profile
Research programme: immunotherapeutics - PHAXIAM Therapeutics
Alternative Names: ERY-TOL; Gr-TolLatest Information Update: 28 Jun 2023
Price :
$50
*
At a glance
- Originator ERYtech Pharma
- Developer PHAXIAM Therapeutics
- Class Peptides; Proteins
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Autoimmune disorders; Immunological disorders
Most Recent Events
- 26 Jun 2023 Pherecydes Pharma has merged with ERYtech Pharma to form PHAXIAM Therapeutics
- 16 Jul 2016 No recent reports of development identified for preclinical development in Autoimmune-disorders in France (Parenteral)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Immunological-disorders in France (Parenteral)